Generation Bio

Generation Bio Financial Leverage

Delisted

The Financial Leverage (Equity Multiplier) of Generation Bio (GBIO) as of Nov 10, 2026 is 2.68. In the previous year, Financial Leverage (Equity Multiplier) was 1.84 — a change of 45.37% (higher).

Financial Leverage

2.68

YoY

45.37%

Last updated:

Financial Leverage (Equity Multiplier) of Generation Bio is 2024 2.68 . Financial Leverage (Equity Multiplier) of Generation Bio was 2023 1.84 . It decreases by 45.37% higher compared to the previous year.

The Generation Bio Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-2.01 USD
Jan 1, 2019
-0.43 USD
Jan 1, 2020
1.10 USD
Jan 1, 2021
1.25 USD
Jan 1, 2022
1.33 USD
Jan 1, 2023
1.84 USD
Jan 1, 2024
2.68 USD
The Generation Bio Financial Leverage history
YEARFinancial LeverageYoY
2.68+45.37%
1.84+38.51%
1.33+6.65%
1.25+13.79%
1.10-356.78%
-0.43-78.72%
-2.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Financial Leverage (Equity Multiplier) of Generation Bio is 2.68 in 2024.

Financial Leverage (Equity Multiplier) of Generation Bio changed from 1.84 to 2.68, representing a 45.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Generation Bio since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Generation Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Generation Bio

All Key Metrics — Generation Bio